Brain tumour treatment developer Extruded Pharmaceuticals reversed into Amur Minerals Corporation, which had sold its mining asset and become a shell, to form CRISM Therapeutics Corporation on 31 May. There was a one-for-160 share consolidation prior to the readmission.
The shell had cash in it, but it will not last long. Management believes that there is enough to start a phase II clinical trial for the ChemoSeed implantable, bioresorbable drug delivery platform.
The opening share price was 24p, but it ended the day at 11.5p after more than 145,000 shares were traded – mainly sells. Th...
